melatonin has been researched along with Cytokine Release Syndrome in 5 studies
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin is a molecule with multiple activities on a virus infection." | 2.82 | Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality. ( Reiter, RJ; Tan, DX, 2022) |
| "Melatonin has been proposed as a safe therapeutic agent for COVID-19 recently, having been given with a US Food and Drug Administration emergency authorized cocktail, REGEN-COV2, for management of COVID-19 progression." | 2.72 | Melatonin interferes with COVID-19 at several distinct ROS-related steps. ( Abu-Soud, HM; Bai, D; Camp, OG; Gonullu, DC; Nayak, N, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, DX | 1 |
| Reiter, RJ | 2 |
| Huo, C | 1 |
| Tang, Y | 1 |
| Li, X | 1 |
| Han, D | 1 |
| Gu, Q | 1 |
| Su, R | 1 |
| Liu, Y | 1 |
| Liu, G | 1 |
| Hu, Y | 1 |
| Yang, H | 1 |
| Artigas, L | 1 |
| Coma, M | 1 |
| Matos-Filipe, P | 1 |
| Aguirre-Plans, J | 1 |
| Farrés, J | 1 |
| Valls, R | 1 |
| Fernandez-Fuentes, N | 1 |
| de la Haba-Rodriguez, J | 1 |
| Olvera, A | 1 |
| Barbera, J | 1 |
| Morales, R | 1 |
| Oliva, B | 1 |
| Mas, JM | 1 |
| Şehirli, AÖ | 1 |
| Sayıner, S | 1 |
| Camp, OG | 1 |
| Bai, D | 1 |
| Gonullu, DC | 1 |
| Nayak, N | 1 |
| Abu-Soud, HM | 1 |
2 reviews available for melatonin and Cytokine Release Syndrome
| Article | Year |
|---|---|
Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality.
Topics: Anti-Inflammatory Agents; Antioxidants; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome | 2022 |
Melatonin interferes with COVID-19 at several distinct ROS-related steps.
Topics: Anti-Inflammatory Agents; Antioxidants; Apoptosis; COVID-19; COVID-19 Drug Treatment; Cytokine Relea | 2021 |
3 other studies available for melatonin and Cytokine Release Syndrome
| Article | Year |
|---|---|
Melatonin alleviates lung injury in H1N1-infected mice by mast cell inactivation and cytokine storm suppression.
Topics: Animals; Cytokine Release Syndrome; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lung; | 2023 |
In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.
Topics: Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndro | 2020 |
Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients.
Topics: Antioxidants; Circadian Rhythm; COVID-19; Cytokine Release Syndrome; Humans; Immune System; Indoles; | 2021 |